Our Mission:
To make precision health services
standard care for a healthier world
myDNA is a world leader in precision health, delivering clinically validated DNA insights to support healthcare providers, laboratories, and health systems. Our solutions enable personalised prescribing, risk stratification, and preventative care, advancing healthcare from reactive to proactive. Through continuous innovation, we support the global shift toward data-driven, individualised healthcare.
We empower healthcare practitioners with evidence-based insights to support precision medicine.
Our pharmacogenomic reports help optimise prescribing across mental health, cardiovascular, gastroenterology, pain, and oncology. Working with leading pathology labs, hospitals, and pharmacies, myDNA delivers clinical testing and reporting at scale.
Our product portfolio also includes nutrigenomics for personalised nutrition and fitness, as well as hereditary risk screening for conditions such as cancer, cardiovascular disease, and neurodegenerative disorders.
myDNA success is driven by a dedicated team of pharmacogenomic specialists, including clinical geneticists, clinical pharmacologists, bioinformaticians, and pharmacists. This expertise allows them to provide leading pharmacogenomic reporting solutions to laboratories across the globe.
Today, myDNA and Gene by Gene offer services around the world.
With over 20 years of experience in providing genetic testing services, and 15 years specifically in delivering pharmacogenomic solutions worldwide, myDNA and its fully owned subsidiary, Gene by Gene, are pioneers in the field.
Our NATA accredited Laboratory is located in Melbourne Australia and our CAP, CLIA accredited Laboratory is located in Houston Texas, providing a full suite of genetic tests for precision medicine.
Our Story:
From groundbreaking beginnings
to a global leader
Our story began in 1976 when our co-founder, Associate Professor Leslie Sheffield, became the first qualified clinical geneticist in Australia. A true pioneer in the field, his leadership at the Royal Women’s and Children’s Hospitals helped introduce groundbreaking genetic screenings, including the first for Down’s syndrome in pregnant women.
This legacy of innovation continued in
2007 with the founding of myDNA.
Our mission: to eradicate guesswork from healthcare. We launched our first pharmacogenomics test, making it accessible to more people with a simple at-home swab. This innovation allows healthcare professionals to make more accurate prescribing decisions based on a patient’s unique genetic makeup.
Building on this success, we expanded into nutrigenetics with our Personalised Wellness Test and a suite of advanced practitioner tests. Guided by Dr. Carlotta Petti, our Scientific Director, we are constantly pushing the boundaries of actionable science.
In January 2021, myDNA acquired Gene by Gene in Houston, Texas, a move that accelerated our global expansion and bolstered our laboratory capabilities with over 20 years of service innovation and state-of-the-art automation. This acquisition strengthened our ability to provide high-throughput clinical testing, including next-generation sequencing.
In 2025, myDNA was acquired by DBG Group, one of Australia’s largest pharmaceutical companies. Dennis Bastas, a long-time investor and advocate for our mission, saw the synergy between our precision health solutions and DBG’s broader portfolio of health, wellness, and beauty brands. This partnership allows us to further scale our mission of building a healthier world.
